Detection of urinary levels of matrix metalloproteinase-7 and tumor necrosis factor-like weak inducer of apoptosis in patients with IgA nephropathy and values in predicting disease progression

Ma Yong-duo; Wang Cong; Li Hai-xiang; Wu Huan

doi:10.3969/j.issn.1671-2390.2022.05.006

Journal of Clinical Nephrology > 2022 > 22(5): 382-387. > DOI: 10.3969/j.issn.1671-2390.2022.05.006

Ma Yong-duo, Wang Cong, Li Hai-xiang, Wu Huan. Detection of urinary levels of matrix metalloproteinase-7 and tumor necrosis factor-like weak inducer of apoptosis in patients with IgA nephropathy and values in predicting disease progression[J]. Journal of Clinical Nephrology, 2022, 22(5): 382-387. DOI: 10.3969/j.issn.1671-2390.2022.05.006

Citation:

PDF (1070 KB)

Detection of urinary levels of matrix metalloproteinase-7 and tumor necrosis factor-like weak inducer of apoptosis in patients with IgA nephropathy and values in predicting disease progression

Department of Nephrology, Municipal People's Hospital, Danzhou 571799, China

More Information

Received Date: August 01, 2021
Available Online: May 11, 2023
Published Date: May 27, 2022

Graphical Abstract

Abstract

Abstract

Objective To explore the expressions of urinary matrix metalloproteinase-7(MMP-7) and tumor necrosis factor-like weak inducer of apoptosis(TWEAK) in patients with IgA nephropathy (IgAN) and examine its predictive value. Methods From January 2018 to March 2021, 115 IgAN patients and 50 normal subjects(control group) were selected. Based upon the progress of IgAN, 115 cases of IgAN patients were divided into two groups of IgAN progressive(n=42) and IgAN non-progressive(n=73). According to the IgAN Oxford classification criteria, they were assigned into two groups of MESTC ≥ 3(n=45) and MEST-C<3(n=70). The levels of urinary MMP-7 and TWEAK were compared between two groups. Multivariate Logistic regression was utilized for analyzing the risk factors of IgAN progression. Receiver operating characteristic(ROC) curve was plotted for examining the values of urinary MMP-7 and TWEAK levels in predicting IgAN progression. Results The levels of urinary MMP-7 (15.72±7.85 vs 6.92±0.53 ng/mL) and TWEAK were significantly higher in IgAN progressive group than those in IgAN non-progressive group[(958.47±42.60) vs(206.73±15.18) ng/mL, P<0.001]. The levels of urinary MMP-7[(23.92±9.27) vs(18.15±8.36) ng/mL]and TWEAK[(1408.70±71.15) vs(1036.28±50.72) ng/mL]were significantly higher in MEST-C ≥ 3 score group than those in MEST-C<3 score group(P<0.001). Multivariate Logistic regression analysis indicated that elevated levels of MMP-7[OR=2.986 95%CI(2.146,-8.513)] and TWEAK[OR=3.370 95%CI (2.752, -10.118)]were the risk factors affecting the progression of IgAN. Receiver operating characteristic(ROC) curve indicated that the area under the curve(AUC) of MMP-7 and TWEAK in predicting IgAN progression was 0.948(95% CI 0.885-0.997) with a sensitivity of 97.5% and a specificity of 85.0%. Correlation analysis indicated that the urinary levels of MMP-7 and TWEAK were significantly positively correlated with M, E, S and T(P<0.001). Conclusion The elevated urinary levels of MMP-7 and TWEAK are the risk factors affecting the progression of IgAN. Both may be used as biological indicators for predicting the progression of IgAN.
- Glomerulonephritis, IgA,
- Matrix metalloproteinase-7,
- Tumor necrosis factor-like weak inducer of apoptosis

FullText(HTML)

References (17)

References

[1]	Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy:an interesting autoimmune kidney disease[J]. Am J Med Sci, 2021, 361(2):176-194. DOI:10. 1016/j. amjms. 2020. 10. 003.
[2]	Zhang J, Ren PP, Wang YC, et al. Serum matrix metalloproteinase-7 level is associated with fibrosis and renal survival in patients with IgA nephropathy[J]. Kidney Blood Press Res, 2017, 42(3):541-552. DOI:10. 1159/000477132.
[3]	Poveda J, Vázquez-Sánchez S, Sanz AB, et al. TWEAK-Fn14 as a common pathway in the heart and the kidneys in cardiorenal syndrome[J]. J Pathol,2021,254(1):5-19. DOI:10. 1002/path. 5631.
[4]	谢燕, 陈源汉, 梁馨苓, 等. IgA肾病预后评估模型的研究进展[J]. 中华肾脏病杂志, 2021, 37(3):234-238. DOI:10. 3760/cma. j. cn441217-20200915-00037. Xie Y, Chen YH, Liang XL, et al. Research progress on prognostic evaluation models of IgA nephropathy[J]. Chin J Nephrol, 2021, 37(3):234-238. DOI:10. 3760/cma. j. cn441217-20200915-00037:
[5]	Miyabe Y, Karasawa K, Akiyama K, et al. Grading system utilising the total score of Oxford classification for predicting renal prognosis in IgA nephropathy[J]. Sci Rep, 2021, 11(1):3584.DOI:10. 1038/s41598-021-82967-x.
[6]	Alexander S,Varughese S,Franklin R,et al. Epidemiology, baseline characteristics and risk of progression in the first SouthAsian prospective longitudinal observational IgA nephropathy cohort[J]. Kidney Int Rep, 2020, 6(2):414-428. DOI:10. 1016/j. ekir. 2020. 11. 026.
[7]	Liu Z, Tan RJ, Liu YH. The many faces of matrix metalloproteinase-7 in kidney diseases[J]. Biomolecules, 2020, 10(6):960. DOI:10. 3390/biom10060960.
[8]	Bernardi S,Voltan R,Rimondi E,et al. TRAIL,OPG,and TWEAK in kidney disease:biomarkers or therapeutic targets?[J]. Clin Sci(Lond), 2019, 133(10):1145-1166. DOI:10. 1042/CS20181116.
[9]	Salem MN, Taha HA, Abd El-Fattah El-Feqi M, et al. Urinary TNF-like weak inducer of apoptosis(TWEAK) as a biomarker of lupus nephritis[J]. Z Rheumatol, 2018, 77(1):71-77. DOI:10. 1007/s00393-016-0184-1.
[10]	刘其锋, 李莎莎. TWEAK与肾脏疾病研究进展[J]. 国际泌尿系统杂志, 2016, 36(3):472-475. DOI:10. 3760/cma. j. issn. 1673-4416. 2016. 03. 048. Liu QF, Li SS. Research progress of tweak and kidney disease[J]. International Journal of Urology, 2016, 36(3):472-475. DOI:10. 3760/cma. j. issn. 1673-4416. 2016. 03. 048.
[11]	Yeter HH, Gonul I, Guz G, et al. Combining clinical features and MEST-C score in IgA nephropathy may be a better determinant of kidney survival[J]. Rom J Intern Med, 2020, 58(4):209-218. DOI:10. 2478/rjim-2020-0025.
[12]	Bobart SA, Alexander MP, Shawwa K, et al. The association of microhematuria with mesangial hypercellularity,endocapillary hypercellularity, crescent score and renal outcomes in immunoglobulin A nephropathy[J]. Nephrol Dial Transplant, 2019, 36(5):840-847. DOI:10. 1093/ndt/gfz267.
[13]	Han X, Xiao Y, Tang Y, et al. Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome[J]. Clin Exp Med, 2019, 19(4):479-486. DOI:10. 1007/s10238-019-00580-9.
[14]	Wang GB, Wu LL, Su HJ, et al. Association of urinary matrix metalloproteinase 7 levels with incident renal flare in lupus nephritis[J]. Arthritis Rheumatol,2021,73(2):265-275. DOI:10. 1002/art. 41506.
[15]	Zhou D, Tian Y, Sun L, et al. Matrix metalloproteinase-7 is a urinary biomarker and pathogenic mediator of kidney fibrosis[J]. J Am Soc Nephrol,2017,28(2):598-611. DOI:10. 1681/ASN. 2016030354.
[16]	Kim JS, Jeong KH. Clinical significance of urinary tumor necrosis factor-like weak inducer of apoptosis(TWEAK) in immunoglobulin A nephropathy[J]. Clin Nephrol, 2020, 93(2):99-105. DOI:10. 5414/CN109821.
[17]	Yang XB, Ou J, Zhang H, et al. Urinary matrix metalloproteinase 7 and prediction of IgA nephropathy progression[J]. Am J Kidney Dis, 2020, 75(3):384-393. DOI:10. 1053/j. ajkd. 2019. 07. 018.

Cited By

Get Citation

PDF

XML

Article views (122) PDF downloads (199)

Turn off MathJax

Article Contents

Abstract

References

Detection of urinary levels of matrix metalloproteinase-7 and tumor necrosis factor-like weak inducer of apoptosis in patients with IgA nephropathy and values in predicting disease progression

Abstract

References

Catalog

Export File

Citation

Format

Content